36. Epidermolysis bullosa
147 clinical trials,   170 drugs   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways

Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02960997
(ClinicalTrials.gov)
May 201615/6/2016Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus, 2%;Drug: VehicleStanford UniversityNULLActive, not recruiting4 YearsN/AAll8Phase 2United States
2NCT03016715
(ClinicalTrials.gov)
May 20169/1/2017Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus 2%;Drug: VehiclePremier Specialists, AustraliaNULLRecruiting5 YearsN/AAll8Phase 2Australia